Silence Therapeutics PLC traded at $4.95 this Monday February 2nd, increasing $0.13 or 2.70 percent since the previous trading session. Looking back, over the last four weeks, Silence Therapeutics gained 16.53 percent. Over the last 12 months, its price fell by 2.17 percent. Looking ahead, we forecast Silence Therapeutics PLC to be priced at 4.72 by the end of this quarter and at 4.45 in one year, according to Trading Economics global macro models projections and analysts expectations.
Silence Therapeutics plc, incorporated on November 18, 1994, is a biotechnology company. The Company is focused on discovering and developing molecules combining short interfering ribonucleic acid (siRNA), to inhibit the expression of target genes in the pathology of diseases with unmet medical need. Its siRNA molecules are designed to harness the body’s natural mechanism of RNA interference (RNAi), by specifically binding to and degrading messenger RNA (mRNA), molecules that encode specific targeted disease-associated proteins in a cell. The Company’s mRNAi GOLD (GalNAc Oligonucleotide Discovery) platform is a platform of precision-engineered medicines designed to target for specific disease-associated genes in the liver. The Company’s clinical development programs include SLN360, for the prevalent unmet need in reducing cardiovascular risk in people born with Lipoprotein(a) levels and SLN124, for rare hematological conditions, including thalassemia, myelodysplastic syndrome (MDS), and polycythemia vera (PV).